PPCB

distress 10/10 · high distress / dilution risk

$1.43-1%today-99% from 52w high

propanc.com1 employeesFounded 2007Camberwell, VICBiotechnology

Revenue

pre-revenue

Liquidity

$0M

Runway

0.0 yrs

Shares 1y

+345%

Price & events

-78.5% over 6M

CatalystRating changeDilutionFinancingdashed = today

-0.7%

-10.1%

-2.7%

-50.7%

-79.6%

-98.7%

+3475.0%

-99.9%

-100.0%

All

Overview

Market Cap: $81.45M
Enterprise Value: $81.51M
Volume: 3.58K
52 Week Range: $1.35 – $260
Total Shares: 56.96M
Float Shares: 1.94M
Short %: 0.83%
% Held by Insiders: 14.85%
% Held by Institutions: 0.81%
RVOL: 0.00x
Beta: 3.30

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 0

No catalyst news yet.

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 56,959,280 · 4 offerings/1y · 3 PIPEs

2026-07-17S-1shelf_registration
2026-04-20EFFECTshelf_effective
2026-04-10S-1shelf_registration
2026-03-06424B3offering
2026-02-24EFFECTshelf_effective
2026-02-19S-1/Ashelf_registration
2026-02-02S-1shelf_registration

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

no recent rating changes

Competitors

none identified